The dilemma with comparing efficacy of OAB treatments

被引:0
|
作者
Sahai, Arun [1 ]
Malde, Sachin [1 ]
机构
[1] Guys Hosp, Dept Urol, Funct Urol Unit, London SE1 9RT, England
关键词
OVERACTIVE BLADDER OAB; URINARY-INCONTINENCE; THERAPY; TRIALS;
D O I
10.1038/nrurol.2017.67
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The comparative efficacy of drugs for the management of overactive bladder syndrome (OAB) remains undefined. A new indirect treatment comparison demonstrates similar efficacy of mirabegron versus several antimuscarinic drugs and onabotulinum toxin A in a number of outcome measures. Head-to-head trials of these agents are still required to optimize the management of patients with OAB.
引用
收藏
页码:393 / +
页数:2
相关论文
共 50 条